VSTM · Verastem, Inc. · Webcasts, Transcripts & Audio
$9.91
-0.20 (-1.93%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, given the risks associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment and do not alleviate the substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to generate sufficient net product revenues or obtain additional capital on favorable terms or at all.”View the 10-Q filed Aug 6, 2026
Market Cap
$901.11M
Shares
90.56M
Volume · Oct 28
2.17M
Avg daily vol (3M)
3.24M
Verastem, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Verastem, Inc. (VSTM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Verastem, Inc. (VSTM) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Confident tone
VS7375 KRAS G12D inhibitor development
Pipeline and registration-directed studies
Earlier line of therapy and physician adoption trends
Revenue
$40.08M
▲ 1775.4% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-23
Verastem, Inc. (VSTM) June 23, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Verastem, Inc. (VSTM) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-20
Verastem, Inc. (VSTM) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Positive tone
VS-7375 KRAS G12D pipeline
Registration-directed Phase II trials
AVMAPKI FAKZYNJA CO-PACK launch performance
Revenue
$18.67M
Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Positive tone
Pancreatic Cancer (RAMP 205)
VS-7375 KRAS G12D Program
LGSOC Commercial Launch
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
Confident tone
VS-7375 KRAS G12D on/off inhibitor program
Commercial launch execution and physician engagement
Reimbursement and patient access
Revenue
$11.24M
Diluted EPS
$-1.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Confident tone
AVMAPKI FAKZYNJA CO-PACK launch
Commercial execution and sales force
KRAS-mutated recurrent LGSOC
Revenue
$2.14M
▼ 78.6% YoY Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Verastem, Inc. (VSTM) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q1
2020-04-27
Verastem, Inc. (VSTM) Q1 2020 Earnings Call
Revenue
$5.06M
▲ 202.6% YoY Diluted EPS
$-4.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-28
Verastem, Inc. (VSTM) Q4 2019 Earnings Call
Revenue
$3.62M
▲ 198.9% YoY Diluted EPS
$-6.12
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Showing 1–12 of 12 webcasts
Key facts
CIK
1526119
CUSIP
92337C203
13F (30d)
21 filings
21 filers
Visit website
Investor relations